Immunome, Inc.(IMNM)

$19.96▲0.56 (2.89%)

Chart

Immunome, Inc.(IMNM)

NASDAQ

$19.96▲0.56 (2.89%)

Chart Studio

IMNM(IMNM)

IMNM

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.51

Aug 5, 2026 · Reports before open

Revenue Estimate

$166,667

FY2030E EPS$1.16

Analyst Sentiment

Wall St. Consensus

Buy

13 analysts·Moderate coverage

Score

13 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

13100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$33.00

+65.3%

Consensus

$36.50

+82.9%

Bull

$40.00

+100.4%

12-Month Target Range13 analysts

$33.00$36.50$40.00

Current $19.96Consensus

Current Price

$19.96

Upside to Consensus

$16.54

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+2073.16%

EPS—

FY2028

Rev+290.64%

EPS—

FY2029

Rev+74.70%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$3M	$59M	$231M	$403M	$613M
Low	$564,430	$15M	$224M	$84M	$127M
High	$5M	$106M	$237M	$793M	$1.21B
EBITDA Avg	$-543,333	$-12M	$-46M	$-81M	$-123M
Low	$-1M	$-21M	$-47M	$-159M	$-241M
High	$-112,885	$-3M	$-45M	$-17M	$-25M
EBIT Avg	$-543,333	$-12M	$-46M	$-81M	$-123M
Low	$-1M	$-21M	$-47M	$-159M	$-241M
High	$-112,885	$-3M	$-45M	$-17M	$-25M
Net Income Avg	$-188M	$-190M	$-139M	$-7M	$101M
Low	$-195M	$-222M	$-206M	$-16M	$-3M
High	$-181M	$-158M	$-36M	$216,437	$228M
EPS Avg	$-2.14	$-2.16	$-1.12	$-0.08	$1.16
Low	$-2.24	$-2.54	$-2.35	$-0.19	$-0.03
High	$-2.07	$-1.81	$-0.41	$0.00	$2.61
Analysts (Rev / EPS)	8 / 10	8 / 9	9 / 8	4 / 6	4 / 6

Quarterly

Metric	Q2 2026	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$166,667	$166,667	$2M	$5M	$10M	$20M	$28M
Low	$166,667	$166,667	$2M	$5M	$10M	$20M	$28M
High	$166,667	$166,667	$2M	$5M	$10M	$20M	$28M
EBITDA Avg	$-33,333	$-33,333	$-476,666	$-986,351	$-2M	$-4M	$-6M
Low	$-33,333	$-33,333	$-476,666	$-986,351	$-2M	$-4M	$-6M
High	$-33,333	$-33,333	$-476,666	$-986,351	$-2M	$-4M	$-6M
EBIT Avg	$-33,333	$-33,333	$-476,666	$-986,351	$-2M	$-4M	$-6M
Low	$-33,333	$-33,333	$-476,666	$-986,351	$-2M	$-4M	$-6M
High	$-33,333	$-33,333	$-476,666	$-986,351	$-2M	$-4M	$-6M
Net Income Avg	$-58M	$-63M	$-67M	$-67M	$-60M	$-56M	$-63M
Low	$-64M	$-67M	$-67M	$-67M	$-60M	$-56M	$-63M
High	$-55M	$-61M	$-67M	$-67M	$-60M	$-56M	$-63M
EPS Avg	$-0.51	$-0.56	$-0.59	$-0.59	$-0.53	$-0.50	$-0.55
Low	$-0.56	$-0.59	$-0.59	$-0.59	$-0.53	$-0.50	$-0.55
High	$-0.48	$-0.54	$-0.59	$-0.59	$-0.53	$-0.50	$-0.55
Analysts (Rev / EPS)	6 / 8	6 / 9	5 / 7	3 / 3	3 / 3	3 / 4	3 / 3

Earnings Surprises

Recent Analyst Actions

May 28, 2026Truist Financial

Immunome Inc. (IMNM) PT Raised to $37 at Truist Securities, Assumes Coverage

Target:$37.00

+67.3%from $22.11

May 28, 2026Barclays

Barclays Starts Immunome Inc. (IMNM) at Overweight

Target:$36.00

+62.8%from $22.11

May 15, 2026Leerink Partners

Immunome price target lowered to $33 from $37 at Leerink

Target:$33.00

+49.9%from $22.02

Feb 12, 2026H.C. Wainwright

Immunome initiated with a Buy at H.C. Wainwright

Target:$40.00

+70.9%from $23.41

Dec 16, 2025Lake Street

Immunome price target raised to $32 from $22 at Lake Street

Target:$32.00

+36.8%from $23.39

Dec 16, 2025Evercore ISI

Immunome price target raised to $40 from $18 at Evercore ISI

Target:$40.00

+71.3%from $23.35

Dec 15, 2025Leerink Partners

Immunome price target raised to $40 from $38 at Leerink

Target:$40.00

+76.6%from $22.65

Dec 1, 2025Truist Financial

Immunome initiated with a Buy at Truist

Target:$36.00

+95.4%from $18.42

Nov 17, 2025Stephens

Immunome Inc. (IMNM) PT Raised to $33 at StephensMember Login

Target:$33.00

+92.5%from $17.14

Sep 5, 2025Craig-Hallum

Immunome initiated with a Buy at Craig-Hallum

Target:$26.00

+147.1%from $10.52

Aug 22, 2025Evercore ISI

Immunome initiated with an Outperform at Evercore ISI

Target:$18.00

+74.8%from $10.30

Aug 13, 2024Piper Sandler

Immunome price target lowered to $23 from $27 at Piper Sandler

Target:$23.00

+82.0%from $12.64

Apr 15, 2024Guggenheim

Immunome initiated with a Buy at Guggenheim

Target:$35.00

+70.1%from $20.58

Apr 1, 2024Wedbush

Immunome price target raised to $33 from $27 at Wedbush

Target:$33.00

+33.7%from $24.68

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance